Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
OBI-3424 by OBI Pharma for Salivary Gland Cancer: Likelihood of Approval
OBI-3424 is under clinical development by OBI Pharma and currently in Phase II for Salivary Gland Cancer. According to GlobalData,...
Data Insights
OBI-3424 by OBI Pharma for Breast Cancer: Likelihood of Approval
OBI-3424 is under clinical development by OBI Pharma and currently in Phase II for Breast Cancer. According to GlobalData, Phase...